Sophia Danhof
Overview
Explore the profile of Sophia Danhof including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
36
Citations
1065
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vera-Cruz S, Jornet Culubret M, Konetzki V, Alb M, Friedel S, Hudecek M, et al.
Cancers (Basel)
. 2024 Nov;
16(22).
PMID: 39594822
Multiple myeloma (MM) treatment remains challenging due to its relapsed/refractory disease course as well as intra- and inter-patient heterogeneity. Cellular immunotherapies, especially chimeric antigen receptor (CAR)-T cells targeting B cell...
2.
Munawar U, Zhou X, Prommersberger S, Nerreter S, Vogt C, Steinhardt M, et al.
Commun Biol
. 2023 Dec;
6(1):1299.
PMID: 38129580
The treatment landscape in multiple myeloma (MM) is shifting from genotoxic drugs to immunotherapies. Monoclonal antibodies, immunoconjugates, T-cell engaging antibodies and CART cells have been incorporated into routine treatment algorithms,...
3.
Scheller L, Tebuka E, Rambau P, Einsele H, Hudecek M, Prommersberger S, et al.
Leuk Lymphoma
. 2023 Nov;
65(2):143-157.
PMID: 37997705
Although the approval of new drugs has improved the clinical outcome of multiple myeloma (MM), it was widely regarded as incurable over the past decades. However, recent advancements in groundbreaking...
4.
Bittrich M, Hetterich R, Solimando A, Krebs M, Loda S, Danhof S, et al.
Clin Exp Med
. 2023 Oct;
23(8):5215-5226.
PMID: 37805620
In addition to randomized clinical trials, consideration of Real-World Evidence is necessary for mirroring clinical reality. However, processing such evidence for large numbers of patients often requires considerable time and...
5.
Garcia-Guerrero E, Rodriguez-Lobato L, Sierro-Martinez B, Danhof S, Bates S, Frenz S, et al.
Haematologica
. 2023 Feb;
108(2):568-580.
PMID: 36722406
B-cell maturation antigen (BCMA) is the lead antigen for chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma (MM). A challenge is inter- and intra-patient heterogeneity in BCMA expression on...
6.
Fischer J, Knop S, Danhof S, Einsele H, Keller D, Loffler C
BMC Cancer
. 2022 Oct;
22(1):1032.
PMID: 36192719
Background: Multiple myeloma (MM) is the third most common hematologic malignancy with increasing importance due to improving treatment strategies and long-term outcomes in an aging population. This study aims to...
7.
Maucher M, Srour M, Danhof S, Einsele H, Hudecek M, Yakoub-Agha I
Cancers (Basel)
. 2021 Dec;
13(24).
PMID: 34944782
Adoptive transfer of gene-engineered chimeric antigen receptor (CAR)-T-cells has emerged as a powerful immunotherapy for combating hematologic cancers. Several target antigens that are prevalently expressed on AML cells have undergone...
8.
Garcia-Guerrero E, Gotz R, Doose S, Sauer M, Rodriguez-Gil A, Nerreter T, et al.
Leukemia
. 2021 Nov;
36(1):297.
PMID: 34845317
No abstract available.
9.
Zhou X, Ruckdeschel A, Peter J, Bockle D, Hornburger H, Danhof S, et al.
Hematol Oncol
. 2021 Nov;
40(2):202-211.
PMID: 34796520
The multi-agent therapy "VDT-PACE" represents an established regimen in relapsed/refractory multiple myeloma (RRMM). Here, we report on our experience with a "modified VDT-PACE" incorporating new generation anti-MM agents daratumumab and...
10.
Luu M, Riester Z, Baldrich A, Reichardt N, Yuille S, Busetti A, et al.
Nat Commun
. 2021 Jul;
12(1):4077.
PMID: 34210970
Emerging data demonstrate that the activity of immune cells can be modulated by microbial molecules. Here, we show that the short-chain fatty acids (SCFAs) pentanoate and butyrate enhance the anti-tumor...